All In Biotech

Drug Trial Radar · NCT06119685

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Last checked: Nov 19, 2026Latest source record: Jun 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

128

Planned (sponsor's estimate)

Start

Oct 25, 2023

Primary completion

Dec 30, 2025

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Indapta Therapeutics, INC.Industry
Sponsor type
Industry
First posted
Nov 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.

Conditions

  • NHL
  • Multiple Myeloma
  • Blood Cancer
  • Refractory Non-Hodgkin Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma

Interventions

  • IDP-023Drug

    NK cell therapy

  • RituximabDrug

    Anti-CD20 antibody therapy

  • DaratumumabDrug

    Anti-CD38 antibody therapy

  • Interleukin-2Drug

    Immune cytokine

  • CyclophosphamideDrug

    Lymphodepleting chemotherapy

  • FludarabineDrug

    Lymphodepleting chemotherapy

  • MesnaDrug

    Chemoprotectant

  • IsatuximabDrug

    Anti-CD38 antibody therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Phase 1)Time frame: 1 year
  2. Incidence of dose-limiting toxicities (DLTs) of IDP-023 Monotherapy - (Phase 1)Time frame: up to 21 days
  3. Nature of dose-limiting toxicities (DLTs) of IDP-023 Monotherapy - (Phase 1)Time frame: up to 21 days
  4. Incidence of dose-limiting toxicities (DLTs) of IDP-023 in combination with Isatuximab, Daratumumab or Rituximab - (Phase 1)Time frame: up to 35 days
  5. Nature of dose-limiting toxicities (DLTs) of IDP-023 in combination with Isatuximab, Daratumumab or Rituximab - (Phase 1)Time frame: up to 35 days
  6. Maximum tolerable dose (MTD) or a tolerated dose below MTD - (Phase 1)Time frame: 1 year
  7. For MM: Anti-tumor activity by objective response rate (ORR), complete response (CR), stringent complete response (sCR), very good partial response (VGPR), and partial response (PR) - (Phase 2)Time frame: 2 years
  8. For NHL: Anti-tumor activity by objective response rate (ORR) - (Phase 2)Time frame: 2 years

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Valkyrie Clinical Trials

    Los Angeles, California · Recruiting

  • Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center

    Lake Mary, Florida · Withdrawn

  • Emory University Hospital

    Atlanta, Georgia · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • NYP/Weill Cornell Medical Center

    New York, New York · Withdrawn

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina · Recruiting

  • University Hospitals Cleveland

    Cleveland, Ohio · Recruiting

  • Providence Cancer Institute Franz Clinic

    Portland, Oregon · Withdrawn

  • Rhode Island Hospital

    Providence, Rhode Island · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Oncology Virginia

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.